In light of the increasing global demand for HMOs, Kyowa Hakko Bio is eyeing opportunities within the Chinese and Thai markets, despite a hazy regulatory environment. Moreover, the company is investing in a new Thai facility to expand its production capacity. Kentaro Yanashima, Research & Business Development for Kyowa Hakko Bio, tells NutritionInsight all about the promising potential of HMO’s for both infant and adult nutrition and the company’s expansion plans.
Upcoming webinars

Why ARA & DHA matter: Key lipids shaping infant development
dsm-firmenich
Register now

Where Structure Drives Beauty: From Scalp Health to Skin Radiance
Monteloeder
Register now

Innovating Skin Supplements: New Folate Evidence for Beauty from Within
Gnosis by Lesaffre
Register now
All upcoming webinars
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement















